Intrathecal serotherapy in neonatal tetanus: a controlled trial.
60 infants with neonatal tetanus were treated at random either by 40 000 units of equine tetanus antitoxin (TAT), intravenously and intramuscularly, or by 40 000 units TAT, IV and IM, plus 150 units of human tetanus immune globulin TIG) intrathecally. There were 30 infants in each treatment group. Babies were similar in age, sex, weight, incubation period, temperature, and signs and symptoms on arrival at the hospital. The mortality rate, days in hospital and days of sedation were not significantly different in the two groups.
D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D007136:Immunoglobulins / Q000008:administration & dosage / Q000627:therapeutic use*; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000628:therapy*; D007278:Injections, Spinal; D008297:Male; D013742:Tetanus / Q000276:immunology / Q000628:therapy*; D013743:Tetanus Antitoxin / Q000627:therapeutic use*
D007136:Immunoglobulins; D013743:Tetanus Antitoxin